Related references
Note: Only part of the references are listed.Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study
Gosta Gahrton et al.
BLOOD (2013)
Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability
Francesca Patriarca et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study
Henk M. Lokhorst et al.
BLOOD (2012)
Bortezomib-Based Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Transplantation
John Koreth et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Laurent Garderet et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant
Amer M. Beitinjaneh et al.
LEUKEMIA & LYMPHOMA (2012)
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
Philip L. McCarthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis
Shaji Kumar et al.
BLOOD (2011)
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial
Evelien Kneppers et al.
BLOOD (2011)
Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma
Larry D. Anderson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up
Bo Bjorkstrand et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial
Amrita Krishnan et al.
LANCET ONCOLOGY (2011)
Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells
Djordje Atanackovic et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma
Henk Lokhorst et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Reduced-intensity allogeneic transplantation for myeloma: reality bites
A. Keith Stewart
BLOOD (2009)
Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma
Nicolaus Kroeger et al.
EXPERIMENTAL HEMATOLOGY (2009)
Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation
Kai Sun et al.
BLOOD (2008)
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma
Laura Rosinol et al.
BLOOD (2008)
Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma
H. de Lavallade et al.
BONE MARROW TRANSPLANTATION (2008)
A comparison of allografting with autografting for newly diagnosed myeloma
Benedetto Bruno et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation
Djordje Atanackovic et al.
BLOOD (2007)
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
F Garban et al.
BLOOD (2006)
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321
B Barlogie et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation
M Mohty et al.
BONE MARROW TRANSPLANTATION (2004)
The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma
HM Lokhorst et al.
BLOOD (2004)
Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect
E Alyea et al.
BONE MARROW TRANSPLANTATION (2003)
Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma.: A phase I/II study of the German Study-group Multiple Myeloma (DSMM)
N Kröger et al.
BONE MARROW TRANSPLANTATION (2003)
Partially T-Cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: A prospective evaluation of patients treated in the phase III study HOVON 24 MM
HM Lokhorst et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation
JA Pérez-Simón et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning
CK Lee et al.
EXPERIMENTAL HEMATOLOGY (2003)
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
DG Maloney et al.
BLOOD (2003)
Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality
N Kröger et al.
BLOOD (2002)
Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma
S Giralt et al.
BONE MARROW TRANSPLANTATION (2002)
Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning
A Badros et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma:: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres
G Gahrton et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Donor leukocyte infusions for multiple myeloma
M Salama et al.
BONE MARROW TRANSPLANTATION (2000)